Letter to Congress Offering Health Care-Related Reforms for Possible Inclusion in Future Cures 2.0 Legislation December 16, 2019
Presentation at the FDA’s Public Hearing Entitled “Standards for Future Opioid Analgesic Approvals and Incentives for New Therapeutics to Treat Pain and Addiction” September 17, 2019
Petition to the FDA for a Moratorium on Approval of New Opioids or New Opioid Formulations March 21, 2019
Letter to the FDA Commissioner Refuting Claims Made in His Public Statement Justifying the Approval of Sufentanil Sublingual Tablets (Dsuvia) December 11, 2018
Letter to the FDA Urging the Agency Not to Approve the New Drug Application for Sufentanil Sublingual Tablets, a Super-Potent Opioid October 18, 2018
Testimony Before the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee Regarding Sublingual Sufentanil Tablets October 12, 2018
Testimony Before the FDA’s Psychopharmacologic Drugs Advisory Committee Regarding Lofexidine March 27, 2018
Testimony Before the FDA’s Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees Regarding A New Extended-Release Oxycodone Product July 26, 2017
Testimony Before the FDA’s Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees Regarding Reformulated Opana ER March 14, 2017